AbbVie

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie Inc. (NYSE: ABBV) heads into the Monday, December 15, 2025 US market open with a familiar “big pharma” setup—steady cash returns, blockbuster execution, and a pipeline that’s increasingly being treated as a source of upside rather than a safety

14 December 2025

AbbVie Stock Outlook (ABBV): Weekly Recap, Fresh Analyst Upgrades, and the Week-Ahead Setup (Updated Dec. 12, 2025)

AbbVie Inc. (NYSE: ABBV) ended the week of Dec. 8–12, 2025 near $223, after a choppy stretch that featured two notable Wall Street moves—an HSBC upgrade and a Morgan Stanley price-target hike—alongside ongoing headlines tied to AbbVie’s oncology and neuroscience

14 December 2025

Analyst Ratings · Investment Strategies · NYSE:ABBV · Pharma Industry · Stock Market · Weekly Recap

AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025

(SEO): AbbVie (NYSE: ABBV) ended the week at $223.32. Here’s what moved ABBV stock this week, the latest news, analyst forecasts and price targets, and what to watch in the week ahead. StockAnalysis Updated:Friday, December 12, 2025 (U.S. market close)

13 December 2025

Financial News · Investing · Market Analysis · NYSE:ABBV · Pharma Industry · Stocks

AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open

AbbVie Inc. (NYSE: ABBV) ended Friday, December 12, 2025, modestly lower, then drifted a bit further down in after-hours trading—an unsurprising outcome on a day when U.S. equities broadly retreated and investors refocused on the macro calendar. Here’s what moved

13 December 2025

AbbVie · After-Hours Trading · Financial News · Investing · NYSE:ABBV · Stock Market

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and

11 December 2025

Dividend Investing · FDA Approvals · Financial News · Pharmaceuticals · Stock Market

AbbVie Stock (ABBV) Today: Price, Dividend Hike, Pipeline Catalysts and 2025–2026 Outlook

AbbVie’s stock is trading just below record highs as investors digest a powerful mix of rising earnings, a fresh dividend increase and a steady drumbeat of positive pipeline news in immunology, neuroscience and oncology. As of the close on Friday,

7 December 2025

Dividend Investing · Financial Analysis · Investment Strategies · NYSE:ABBV · Pharmaceutical Industry · Stock Market

AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 as one of the most closely watched large‑cap healthcare stocks, with fresh dividend news, new oncology and migraine data, and an upbeat earnings outlook all hitting the tape just

2 December 2025

Dividends · Investment Analysis · Market Outlook · NYSE:ABBV · Pharma Industry · Stocks

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock. The

1 December 2025

Earnings Reports · Healthcare Innovation · Investment Analysis · Pharmaceuticals · Stock Market

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie Inc. (NYSE: ABBV) heads into Monday’s December 1, 2025 open sitting near the middle of its recent trading range, with a lot of fresh information for investors to digest from November 28–30. As of the latest close on November

30 November 2025

Healthcare · Investment · Market Analysis · NYSE:ABBV · Pharmaceuticals · Stocks

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 with a mixed but generally constructive backdrop for shareholders. The stock is trading in the mid‑$220s per share — around $227 — implying a market capitalization of roughly $400

30 November 2025

Dividends · FDA Updates · Investment Strategies · NYSE:ABBV · Pharma News · Stock Analysis

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday,

29 November 2025

Company Earnings · Healthcare News · Investment Analysis · NYSE:ABBV · Pharmaceuticals · Stock Market

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Inc. (NYSE: ABBV) ended Friday’s session almost unchanged, closing around $227.70 per share, up a negligible 0.02%, after earlier trading slightly in the red. StockAnalysis+2StockAnalysis+2 Even with today’s flat finish, the pharma giant remains one of 2025’s standout healthcare

28 November 2025

Dividends · Investing · Market News · Pharma Industry · Stocks